

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4411649

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	ESSAM ENAN	11/29/2006
RECEIVING PARTY DATA		
Name:	TYRATECH, INC.	
Street Address:	111 WEST NEW HAVEN AVENUE	
City:	MELBOURNE	
State/Country:	FLORIDA	
Postal Code:	32901	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	15286110
CORRESPONDENCE DATA		
Fax Number:	(412)355-6501	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	412-355-6338	
Email:	piuspatents@klgates.com	
Correspondent Name:	K&L GATES LLP - JAIMIE R. ANDERSON	
Address Line 1:	210 SIXTH AVENUE	
Address Line 2:	K&L GATES CENTER	
Address Line 4:	PITTSBURGH, PENNSYLVANIA 15222-2613	
ATTORNEY DOCKET NUMBER:	TYTCH-024US2CONCON	
NAME OF SUBMITTER:	JAIMIE R. ANDERSON	
SIGNATURE:	/Jaimie R. Anderson/	
DATE SIGNED:	05/12/2017	
Total Attachments: 14		
source=Copy of Parent Assignment-12-936-133#page1.tif		
source=Copy of Parent Assignment-12-936-133#page2.tif		
source=Copy of Parent Assignment-12-936-133#page3.tif		
source=Copy of Parent Assignment-12-936-133#page4.tif		
source=Copy of Parent Assignment-12-936-133#page5.tif		

source=Copy of Parent Assignment-12-936-133#page6.tif
source=Copy of Parent Assignment-12-936-133#page7.tif
source=Copy of Parent Assignment-12-936-133#page8.tif
source=Copy of Parent Assignment-12-936-133#page9.tif
source=Copy of Parent Assignment-12-936-133#page10.tif
source=Copy of Parent Assignment-12-936-133#page11.tif
source=Copy of Parent Assignment-12-936-133#page12.tif
source=Copy of Parent Assignment-12-936-133#page13.tif
source=Copy of Parent Assignment-12-936-133#page14.tif

ASSIGNMENT

WHEREAS we, Essam Enan, a citizen of the United States, residing at 1800 Botticelli Place, Davis, CA 95618, Ahmad Akashe, a citizen of the United States, residing at 817 Castleton Court, Mundelein, IL 60060, Anilkumar Gaonkar, a citizen of the United States, residing at 2290 Apple Hill Court S., Buffalo Grove, IL 60089 and Leslie George West, a citizen of the United States, residing at 170 N. Sheridan Road, Winnetka, IL 60093, hereinafter referred to as ASSIGNORS, have invented certain new and useful improvements in a PEST CONTROL USING NATURAL PEST CONTROL AGENT BLENDS, the specification of which was filed as International Patent Application No. PCT/US2009/037735 on March 19, 2009, the national phase of which has been assigned U.S. Patent Application No. 12/936,133 (the "Application"); and

WHEREAS, TyraTech, Inc. a Delaware corporation, with a principal place of business at 111 West New Haven Avenue, Melbourne, FL 32901, desire to acquire the entire right, title and interest in, to and under said invention invented by Essam Enan and the United States Letters Patent to be obtained.

WHEREAS, Mondelez Global LLC, with a principle place of business at Three Parkway North, Suite 300, Deerfield, IL 60015, desire to acquire the entire right, title and interest in, to and under said invention invented by Ahmad Akashe, Anilkumar Ganapati, and Leslie George West and the United States Letters Patent to be obtained.

WHEREAS, TyraTech, Inc. and Mondelez Global LLC are hereinafter referred to as ASSIGNEES, are desirous of acquiring the entire right, title and interest in, to and under said invention and the United States Letters Patent to be obtained therefor.

NOW THEREFORE, TO ALL WHOM IT MAY CONCERN:

Be it known that for good and valuable consideration, the receipt of which is hereby acknowledged, the ASSIGNORS hereby declare and confirm that on the date of the Application they did sell, assign, transfer and set over and hereby do sell, assign, transfer and set over unto ASSIGNEES, its successors, legal representatives and assigns, the entire right, title and interest throughout the world in the Application and all provisional applications relating thereto, as well as any improvements made thereto, including any utility (non-provisional) application(s) claiming priority thereto that have been or may hereafter be filed, such filings including divisions, renewals and continuations thereof, and all Letters Patent of the United States which may be granted thereon and all reissues and extensions thereof, and all applications for industrial property protection, including, without limitation, all applications for patents, utility models, and designs which may hereafter be filed for said improvements in any country together with the right to file such applications and the right to claim for the same the priority rights derived from said registration/application under the local patent laws, of the International Convention for the Protection of Industrial Property, or any other international agreement or the domestic laws of the country in which any such application is filed, as may be applicable; and all forms of industrial property protection, including,

without limitation, patents, utility models, inventor's certificates and designs which maybe granted for said improvements in any country and all extensions, renewals and reissues thereof;

ASSIGNORS also hereby declare and confirm that they did sell, assign, transfer and set over and hereby do sell, assign, transfer and set over unto ASSIGNEES, its successors, legal representatives and assigns, the entire right, title and interest in any PCT or international application filed for the same invention in, to and under the said improvements in any country or countries foreign to the United States, and all applications for Letters Patent which may evolve therefrom, including the right to claim International Convention priority.

AND ASSIGNORS HEREBY authorize and request the Commissioner of Patents and Trademarks of the United States, and any Official of any country or countries foreign to the United States, whose duty is to issue patents and other evidence or forms of industrial property protection on registrations/applications as aforesaid, to the same to the said ASSIGNEES, its successors, legal representatives and assigns, in accordance with the terms of this instrument.

AND ASSIGNORS HEREBY covenant and agree that they have full right to convey the entire interest herein assigned, and that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment and sale.

AND ASSIGNORS HEREBY declare that they did sell, assign, transfer, and convey and hereby do sell, assign, transfer and convey unto ASSIGNEES, its successors, legal representatives, and assigns all claims for damages and all remedies arising out of any violation of the rights assigned hereby that may have accrued prior to the date of the assignment to ASSIGNEES, or may accrue hereafter, including, but not limited to, the right to sue for, collect, and retain damages for past infringements of the said Letters Patent before or after issuance.

AND ASSIGNORS DO HEREBY covenant and agree that they will communicate to the said ASSIGNEE, its successors, legal representatives and assigns, all pertinent facts and documents relating to said improvements and to said applications, said invention and said Letters Patent as may be known and accessible to ASSIGNORS, and ASSIGNORS will testify as to the same in any interference or litigation related thereto and will promptly execute and deliver to ASSIGNEES or its legal representative any and all papers, instruments or affidavits required to apply for obtain, maintain and enforce said applications, including all divisional, continuing and reissue applications, said invention and said Letters Patent which may be necessary or desirable to carry out the purposes hereof. ASSIGNORS also agree to make all rightful oaths and generally do everything possible to aid said ASSIGNEES, its successors, legal representatives and assigns, to obtain and enforce proper patent protection for said improvements in all countries.

Date: _____

Essam Enan

STATE OF _____ }
COUNTY OF _____ } ss.

On _____ before me, _____, personally appeared Essam Enan, proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

WITNESS my hand and official seal.

Signature _____ (Seal)

Date: 11/29/12


Ahmad Akashe
Ahmad Akashe

STATE OF Illinois }
COUNTY OF Cook } ss.


On 11/29/12 before me, JoAnn Roszak, personally appeared Ahmad Akashe, proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

WITNESS my hand and official seal.

Signature JoAnn Roszak (Seal)




Date: 11/29/2012



Anilkumar Gaonkar

STATE OF Illinois }
COUNTY OF Cook } ss.

On 11/29/12 before me, JoAnn Roszak, personally appeared Anilkumar Gaonkar, proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

WITNESS my hand and official seal.

Signature  (Seal)



Date: Nov 26, 2012

Leslie George West
Leslie George West

STATE OF


ss.

COUNTY OF

On 11/26/12 before me, Lynn A. McGeown, personally appeared Leslie George West, proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

WITNESS my hand and official seal.

Signature Lynn A. McGeown (Seal)



Application No.: 12/936,133
Filing Date: January 28, 2011

PATENT
Attorney Docket No.: 0088524-024US0

EVIDENCE OF OBLIGATION TO ASSIGN

Attached hereto as Exhibit A is an Agreement between Inventor Essam Enan and Assignee TyraTech, effective November 29, 2006. Also attached as Exhibit B is evidence that Dr. Enan was an employee and officer of TyraTech as of the filing date of the application.

EXHIBIT A

PROPRIETARY INFORMATION, ASSIGNMENT OF INVENTION & NON-COMPETITION AGREEMENT

This Proprietary Information, Assignment of Invention & Non-Competition Agreement (the "Agreement"), dated as of 10 29, 2006, is between TyraTech, LLC, a Delaware limited liability company (the "Company") and Essam Enan, Ph.D. (the "Chief Science Officer").

WHEREAS Chief Science Officer is being engaged to perform services on behalf of the Company, both directly, as the Chief Science Officer of the Company, and indirectly, as a research professor at Vanderbilt University conducting research sponsored by the Company. In connection with such services performed and to be performed by Chief Science Officer, (i) information of a confidential or proprietary nature may be disclosed to the Chief Science Officer by the Company, and (ii) inventions may be made which will be the property of the Company.

WHEREAS the Company desires to protect its legitimate business interest.

NOW, THEREFORE, both parties acknowledge that the Confidential Information (defined below) is a valuable asset of the Company and good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, has been provided for the promises and covenants that follow:

1. Non-Disclosure of Confidential Information.

(a) The Chief Science Officer agrees that Chief Science Officer will not at any time, during or after his relationship with the Company, except as authorized or directed herein or in writing by the Company, as the case may be, use for the Chief Science Officer's own benefit (or for the benefit of any person or entity other than the Company), copy, reveal, sell, exchange or give away, disclose, divulge or make known or available in any manner to any person, firm, corporation or other entity (whether or not the Chief Science Officer receives any benefit therefrom), any Confidential Information, which shall include all knowledge, information and documents of a confidential nature or which is not generally known to the public; provided, however, the term "Confidential Information" shall not include information which is or becomes generally available to the public other than as a result of a breach of this Agreement.

(b) The Chief Science Officer will take all actions necessary to ensure that the Confidential Information of the Company is maintained as secret and confidential. The Chief Science Officer expressly stipulates and agrees that any breach or threatened breach of the obligations imposed by this Section 1 will cause irreparable harm to the Company. The confidentiality obligations contained in this Agreement shall apply irrespective of the novelty, invention, patentability, state of the prior art, and the level of skill in the business, art, or field to which the subject matter of any such

information pertains. Regardless of when the Company takes measures to prevent any such information from becoming available to persons other than those selected by the Company, as the case may be, to have access thereto for limited purposes, a trade secret is considered to be secret, of value, for use or in use by the business, and of advantage to the business, or providing an opportunity to obtain an advantage, over those who do not know or use it.

(c) If Chief Science Officer is requested or required (by oral question, interrogatories, investigative demand or similar process) to disclose any Confidential Information of the Company, Chief Science Officer will promptly notify the Company of such request or requirement prior to any such disclosure so that the Company may seek an appropriate protective order or waive compliance with provisions of this Agreement.

2. Confidential Information; Technology.

(a) "Confidential Information" shall mean (i) any and all trade secrets of the Company; (ii) Technology (defined below); (iii) all information or knowledge belonging to, used by, or which is in the possession of the Company relating to the Company's business, business plans, budgets, forecasts, strategies, pricing, sales methods, clients, vendors, programs, finances, costs, employees (including, without limitation, the names, addresses or telephone numbers of any employees), employee compensation rates or policies, marketing plans, development plans, computer programs, computer systems, inventions, developments, know-how or confidences of the Company or the Company's business, without regard as to whether any of such Confidential Information may be deemed confidential or material to any third party; (iv) any information, discovery or knowledge discovered by the Chief Science Officer from the use of the Confidential Information or otherwise from or through the Company, its agents or related parties, including any improvements to Technology by the Chief Science Officer; (v) any information or materials relating to third parties that are being evaluated by the Company as a potential acquisition target or other business opportunity, including information or materials as to which such third parties may have rights; and (vi) all other information or materials which the Company may from time to time designate and treat as confidential and proprietary or as a trade secret.

(b) The term "Technology" shall include any presently existing or improvements to proprietary technology, know-how, discoveries, inventions, research and development plans and projects, prototypes and related information, whether or not patentable and whether or not reduced to practice, which have been licensed to, acquired by, developed, optioned or owned by the Company, its suppliers or that of third parties that are being evaluated by the Company as a potential opportunity. The term "Technology" shall further include, but not be limited to, mechanical, electronic, computer, engineering and other scientific and practicable information, drawings, specifications, notes, models, techniques, processes, computer software, scientific discoveries, experiments, data, technologies, equipment designs, training, devices, charts, manuals, records, notebooks, other writings, compilations or tangible

embodiments of information created, developed, compiled or otherwise owned by or licensed to the Company or, its suppliers or third persons or entities that are being evaluated by the Company as a potential opportunity, together with all improvements thereto.

(c) Chief Science Officer hereby stipulates to the confidentiality and materiality of the Confidential Information described herein. Chief Science Officer further agrees that he is under no obligation to any person or entity which is in any way inconsistent with this Agreement or which imposes any restriction on behalf of the Company. The Chief Science Officer also acknowledges that he has been instructed that during the term of employment by the Company or while under contract with the Company, Chief Science Officer is not to divulge to the Company, its employees or consultants any confidential information obtained from any previous employers or any other person.

3. Return of Records. All Confidential Information, including, without limitation, records, files memoranda, reports, price lists, customer lists, drawings, plans, sketches, documents, equipment, personnel data, inclusive of employee compensation and otherwise company proprietary data, and the like, relating to the business of the Company, which Chief Science Officer shall use or prepare or come into contact with, shall remain the sole property of the Company. Upon demand of the Company, the Chief Science Officer shall deliver all documentation, records, notes, data, memoranda, models and equipment of any nature, including all copies and/or extracts therefrom, that are or were in the Chief Science Officer's possession or under his control and that are the property of the Company or comprise part of or otherwise relate to the Confidential Information will be returned to the Company immediately upon the Company's request; provided that Confidential Information not so requested or returned will be destroyed and certified by Chief Science Officer to the Company that Chief Science Officer has done so.

4. Inventions, Discoveries and Improvements. Except for inventions which are subject to that certain license agreement between the Company and Vanderbilt University as of June 3, 2004, as it may be amended or restated from time to time, or sponsored research agreements between the Company and Vanderbilt University related to such license, all inventions, discoveries, and improvements, whether patentable, made, devised, or discovered by the Chief Science Officer, whether by himself or jointly with others, during the employment of the Chief Science Officer or while under contract and performing services for the Company, relating to or pertaining in any way to the business of the Company redound to the benefit of the Company and become and remain the sole and exclusive property of the Company. Chief Science Officer shall promptly disclose in writing to the CEO (or such other officer as the CEO may designate) of the Company a written description of any such invention(s). The Chief Science Officer agrees to execute any assignments to the Company or its nominee of his entire right, title and interest in and to any such inventions, discoveries and improvements and to execute any other instruments and documents requisite or desirable in applying for and obtaining patents, at the cost of the Company, with respect

thereto in the United States and in all foreign countries, that may be requested by the Company. The Chief Science Officer further agrees, whether or not then in the employ of the Company or under contract with the Company, to cooperate to the extent and in the manner requested by the Company in the prosecution or defense of any patent claims or any litigation or other proceeding involving any inventions, trade secrets, processes, discoveries, or improvements covered by this Agreement, but all expenses thereof shall be paid by the Company.

5. Other Potentially Conflicting Activities: Chief Science Officer will not, during the term that Chief Science Officer remains the Chief Science Officer or other employee of the Company or otherwise is under contract for services to the Company, (a) accept any other employment other than with Vanderbilt University; (b) engage, directly or indirectly, in any other business activity that might interfere with Chief Science Officer's duties and responsibilities to the Company or create a conflict of interest with the Company; or (c) act either directly or indirectly as a partner, officer, director, stockholder, employee or agent in any firm, corporation, business entity or business enterprise competitive with the business of the Company or its subsidiaries, except with the express written consent of the Board of Directors of the Company. The non-competition prohibitions contained in Section 5(c) above shall apply not only during the term that Chief Science Officer remains the Chief Science Officer or other employee of the Company or otherwise is under contract for services to the Company but shall continue for a period of two (2) years thereafter. .

6. Entire Agreement. This Agreement contains the sole and entire agreement between the parties as to the matters contained herein and integrates and supersedes any and all other agreements between them. To the extent that the practices, policies or procedures of the Company, now or in the future, apply to Chief Science Officer and are inconsistent with the terms of this Agreement, the provisions of this Agreement shall control. Any subsequent change in Chief Science Officer's duties, position, or compensation will not affect the validity or scope of this Agreement.

7. Amendments; Waivers; Remedies. This Agreement may not be amended or waived except by a writing signed by Chief Science Officer and by a duly authorized representative of the Company other than Chief Science Officer. Failure to exercise any right under this Agreement shall not constitute a waiver of such right. Any waiver of any breach of this Agreement shall not operate as a waiver of any subsequent breaches. All rights or remedies specified for a party herein shall be cumulative and in addition to all other rights and remedies of the party hereunder or under applicable law.

8. Assignment; Binding Effect.

(a) The performance of Chief Science Officer is personal hereunder, and Chief Science Officer agrees that Chief Science Officer shall have no right to assign and shall not assign or purport to assign any rights or obligations under this Agreement. This Agreement may be assigned or transferred by the Company. In the event of the sale, merger or consolidation of the Company or any of its assets, Chief Science Officer

agrees that Company may assign its rights and obligations hereunder to its successor or purchaser. Nothing in this Agreement shall prevent the consolidation, merger or sale of the Company or a sale of any or all or substantially all of its assets.

(b) Subject to the foregoing restriction on assignment by Chief Science Officer, this Agreement shall inure to the benefit of and be binding upon each of the parties; the affiliates, officers, directors, agents, successors and assigns of the Company; and the heirs, devisees, spouses, legal representatives and successors of Chief Science Officer.

9. Notices. All notices or other communications required or permitted hereunder shall be made in writing and shall be deemed to have been duly given if delivered (a) by hand or (b) by an internationally recognized overnight courier service or (c) by first class registered or certified mail, return receipt requested, to the principal address of the other party, as set forth below. The date of notice shall be deemed to be the earlier of (i) actual receipt of notice by any permitted means, or (ii) five business days following dispatch by overnight delivery service or first class registered or certified mail. Chief Science Officer shall be obligated to notify the Company in writing of any change in Chief Science Officer's address. Notice of change of address shall be effective only when done in accordance with this paragraph.

Company's Notice Address:

1901 S. Harbor City Blvd.
Suite 300
Melbourne, FL 32901

Chief Science Officer's Notice Address:

10. Severability. If any provision of this Agreement shall be held by a court or arbitrator to be invalid, unenforceable, or void, such provision shall be enforced to the fullest extent permitted by law, and the remainder of this Agreement shall remain in full force and effect. In the event that the time period or scope of any provision is declared by a court or arbitrator of competent jurisdiction to exceed the maximum time period or scope that such court or arbitrator deems enforceable, then such court or arbitrator shall reduce the time period or scope to the maximum time period or scope permitted by law.

11. Governing Law and Venue. This Agreement shall be governed by and construed in accordance with the laws of the State of Florida, United States of America. All actions under this Agreement shall be taken in a court of competent jurisdiction

within Brevard County, Florida and Chief Science Officer hereby waives and agrees that he shall not assert that such forum is inconvenient.

12. Interpretation. This Agreement shall be construed as a whole, according to its fair meaning, and not in favor of or against any party. Sections and section headings contained in this Agreement are for reference purposes only, and shall not affect in any manner the meaning or interpretation of this Agreement. Whenever the context requires, references to the singular shall include the plural and the plural the singular.

13. Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original of this Agreement, but all of which together shall constitute one and the same instrument.

14. Authority. Each party represents and warrants that such party has the right, power and authority to enter into and execute this Agreement and to perform and discharge all of the obligations hereunder; and that this Agreement constitutes the valid and legally binding agreement and obligation of such party and is enforceable in accordance with its terms.

15. Survival. The provisions of this Agreement shall continue and survive for the periods set forth herein unless or until there is a completion and fulfillment of all the conditions, covenants and warranties herein.

16. Chief Science Officer Acknowledgment


CHIEF SCIENCE OFFICER ACKNOWLEDGES CHIEF SCIENCE OFFICER HAS HAD THE OPPORTUNITY TO CONSULT LEGAL COUNSEL CONCERNING THIS AGREEMENT, THAT CHIEF SCIENCE OFFICER HAS READ AND UNDERSTANDS THE AGREEMENT, THAT CHIEF SCIENCE OFFICER IS FULLY AWARE OF ITS LEGAL EFFECT, AND THAT CHIEF SCIENCE OFFICER HAS ENTERED INTO IT FREELY BASED ON CHIEF SCIENCE OFFICER'S OWN JUDGMENT AND NOT ON ANY REPRESENTATIONS OR PROMISES OTHER THAN THOSE CONTAINED IN THIS AGREEMENT.

IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the date first written above.

TYRATECH, LLC


CHIEF SCIENCE OFFICER:

By: _____



Name: Daniel A. Cohen

Title: President



PATENT


REEL: 042355 FRAME: 0572

EXHIBIT B

Essam Enan - 050020 - TyraTech Inc

Current Pay Statement

This is a statement of earnings and deductions. This pay statement is non-negotiable.



TyraTech Inc
5151 McCrimmon Ave
Suite 275
Morrisville, NC 27560
321-409-7713

Pay Statement
Period Start Date 02/06/2011
Period End Date 02/19/2011
Pay Date 02/18/2011
Document 1653
Net Pay REDACTED

Pay Details

Essam Enan 2115 Portland Ave. #304 Nashville, TN 37212 USA	Employee Number 050020 SSN xxxxxxxx Job Chief Science Officer Pay Rate REDACTED Pay Frequency Biweekly	Pay Group Salary Bi-Weekly Location Vanderbilt Department RD - Research & Development	Federal Income Tax M1 State Income Tax (Residence) M1 State Income Tax (Work) M1
---	---	--	---

Earnings

Pay Type	Hours	Pay Rate	Current	YTD
Group Term Life	0.0000	REDACTED		
Holiday	0.0000			
Regular Pay	80.0000 \$			

Total Hours 80.0000

Deductions

Deduction	Pre-Tax	Current	YTD
Group Term Life		REDACTED	

Taxes

Taxes	Current	YTD
Employee Medicare	REDACTED	
Federal Income Tax	REDACTED	
Social Security Employee Tax	REDACTED	

Paid Time Off

Net Pay Distribution

Plan	Current	Balance	Account Number	Account Type	Amount
Personal Time	REDACTED		xxxxxxx4625	Checking	REDACTED
Sick			Total		
Vacation					

Pay Summary

	Gross	FIT Taxable Wages	Taxes	Deductions	Net Pay
Current					
YTD		REDACTED			

Originally printed in English